Through detailed mechanistic exploration, we discovered that ELOVL2 inhibition reverses therapeutic resistance predominantly by regulating the ubiquitin-proteasome pathway, thereby establishing a novel molecular link between fatty acid metabolism and AR signaling in advanced PCa. Here, ELOVL2 is linked to posterior cortical atrophy.